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X chromosome inactivation in female mammals results in dosage compensation of X-linked gene products between the
sexes. In humans there is evidence that a substantial proportion of genes escape from silencing. We have carried out a
large-scale analysis of gene expression in lymphoblastoid cell lines from four human populations to determine the
extent to which escape from X chromosome inactivation disrupts dosage compensation. We conclude that dosage
compensation is virtually complete. Overall expression from the X chromosome is only slightly higher in females and
can largely be accounted for by elevated female expression of approximately 5% of X-linked genes. We suggest that
the potential contribution of escape from X chromosome inactivation to phenotypic differences between the sexes is
more limited than previously believed.
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Introduction
Dosage compensation is a regulatory process that alters
gene expression along entire X chromosomes resulting in
equivalent levels of X-linked gene products in males and
females. Dosage compensation has evolved independently
several times and is achieved in various ways. In Drosophila
melanogaster, for example, the male X chromosome is hyper-
transcribed, doubling the output of X-linked genes (reviewed
in [1] and [2]). This balances gene expression between the
sexes and also satisﬁes the second requirement of a dosage
compensation system, which is to balance X chromosome
gene expression with that of the autosomes. The situation in
mammals is more complex. Inactivation of one of the X
chromosomes in female mammals [3] balances X-linked gene
expression between males and females. However, if this were
the only component of the mammalian system, the single
active X chromosome of females and males would effectively
make both sexes aneuploid with respect to autosome gene
expression. Ohno hypothesized therefore that balance would
be achieved by doubling the output from the male X (and
active female X) [4]. The hypothesis was conﬁrmed recently
when 2-fold upregulation of the X chromosome was
demonstrated for both human [5] and mouse [6].
The molecular mechanism for this X chromosome upre-
gulation in mammals is unknown. By contrast X chromosome
inactivation (XCI) has been known about for almost ﬁfty years
and is extensively characterized. XCI is a complex and tightly
regulated process unique to mammals that results in
heterochromatization and transcriptional silencing of one
of the female X chromosomes (for a review see reference [7]).
In eutherian mammals, the maternal or paternal X chromo-
some is inactivated randomly early in embryogenesis, and
once established the pattern is mitotically stable. XCI was ﬁrst
suggested in 1961 to explain mosaic phenotypes seen in
female mice heterozygous for sex-linked mutations in coat
colour genes [3]. The theory was supported by the observa-
tion that cloned ﬁbroblasts from human females hetero-
zygous for an electrophoretic protein variant from the X-
linked gene G6PD expressed either the paternal or the
maternal allele, but not both [8]. Similar observations were
reported for HPRT [9], PGK [10,11] and a number of other X-
linked genes.
This pattern of complete silencing of one allele in females
is seen for the majority of X-linked genes tested. However, the
ﬁnding that the steroid sulphatase gene (STS) was always
expressed in female ﬁbroblast clones with one STS-deﬁcient
allele, regardless of which X was inactivated, suggested that
some genes are not subject to XCI [12]. This ‘‘escape’’ from
XCI results in differential expression of STS loci on the active
X( X a) and inactive X (Xi) chromosomes: clones expressing
STS from the Xi have approximately half the level of STS
enzyme activity of clones expressing from the Xa [13].
The use of rodent-human hybrid cell lines retaining an
inactive human X chromosome has contributed greatly to our
knowledge of escape from X inactivation [14–16]. This
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expression from the Xi without the interference of the active
copy. The largest study of this type has estimated that
minimally 16% of human genes escape from XCI [16]. In a
complementary approach, the same authors compared
expression from maternal and paternal alleles of 94 genes
in a panel of cell lines with skewed XCI and found that 15%
of these were consistently expressed from both X chromo-
somes [16].
These approaches can detect low levels of expression from
Xi. However, measuring the effect on dosage compensation
requires a method to compare gene expression between the
sexes. Expression microarrays, designed using the annotated
X chromosome sequence [17], are suitable for such compar-
isons. Microarrays have previously been used to identify
human genes escaping XCI by comparing gene expression in
cell lines with supernumerary X chromosomes [18], in male
and female lymphocytes [19], and in a range of male and
female tissues [20]. A genome-wide survey of sex-differences
in gene expression in lymphoblastoid cells also yielded several
examples of X chromosome genes with elevated female
expression levels [21].
In the light of this reported widespread escape from X
inactivation, we sought to determine its effect on dosage
compensation in the largest comparison to date of X
chromosome gene expression in females and males. Here
we report analysis of a microarray expression dataset
obtained using lymphoblastoid cell lines from 210 individuals
in four populations. We show that the proportion of X-linked
genes with signiﬁcantly higher expression in females is
around 5%, and that dosage compensation in these cell lines
is virtually complete.
Results
Expression from the X Chromosome in Male Cell Lines Is
Upregulated 2-Fold
Microarray data from the Gene Expression Variation
project (GENEVAR [22–24]) were analysed for 210 unrelated
individuals from the four HapMap populations [25], desig-
nated CEU, CHB, YRI and JPT (see Methods).
First, we identiﬁed 371 genes on the X chromosome and
11,952 genes on autosomes that are expressed in the cell lines
(see Methods). We then compared gene expression from
autosomes and the male X chromosome. The median
expression value of the 11,952 autosomal genes was plotted
against the median of the 371 X chromosome genes for 105
unrelated male individuals from four populations (Figure
1A). There is a clear linear relationship between autosomal
and X gene expression in all populations. The majority of
Figure 1. Gene Expression from the Single Male X Chromosome Is
Similar to Expression from Autosome Pairs
(A) Scatter graph of median expression of 11,952 autosomal genes
against median expression of 371 X chromosome genes for 105 males.
The diagonal indicates the position at which median expression levels
from X and autosomes are the same.
(B) Median expression for each autosome pair and for X. Medians were
calculated for each gene for 30 YRI males, and then medians were
calculated for each autosome and for X. Data are ranked in order of
increasing median expression.
doi:10.1371/journal.pgen.0040009.g001
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Author Summary
The males and females of many species are distinguished by their
inheritance of different sets of sex chromosomes. This creates a
significant imbalance in gene number between the sexes. Dosage
compensation is the correction for this imbalance and is achieved by
regulating gene activity across entire sex chromosomes. For
example, human females have two X chromosomes and males
have only one. Dosage compensation in humans involves X
chromosome inactivation, which is the silencing of one X
chromosome in female cells. Some genes are known to escape
the silencing process and so are expressed at higher levels in
females than males. We have investigated the extent to which such
genes disrupt dosage compensation by comparing the activity of X
chromosome genes in a large number of human male and female
cell lines. We have shown that gene expression from the X
chromosome pair in female cell lines is only slightly higher than
from the single X in males. The small difference can be accounted
for by increased female expression of approximately 5% of X
chromosome genes. We conclude therefore that dosage compen-
sation in these human cell lines is virtually complete, and we
suggest that differences in X chromosome gene expression between
males and females may be less extensive than previously thought.data points fall along a diagonal close to that where the
autosomal median is equal to the X median. We compared
mean expression of the 371 X genes with randomly selected
sets of 371 autosome genes (n ¼ 100) for 30 YRI males using
Student’s t-test and saw no signiﬁcant difference (data not
shown). Average expression from the single X chromosome in
males is, therefore, similar to expression from an autosome
pair.
Next, we compared the male X chromosome with each
autosome pair separately. Results for the YRI population are
shown in Figure 1B, and very similar results were obtained for
the other populations (data not shown). Median expression
from the single X chromosome falls within the normal range
seen for autosome pairs and is slightly above average. The
latter accounts for the observation that most data points in
Figure 1A lie above the diagonal.
We conclude that expression from the single X in male cell
lines is upregulated 2-fold relative to autosomes, thus
achieving dosage parity between the X and autosomes.
Upregulation occurs precisely and consistently in 105
individual male samples. This supports and extends the
ﬁndings of Nguyen and Disteche [5].
The Contribution of the Inactive X Chromosome in
Females Is Small
The two X chromosomes in females are not equivalent as
the majority of genes on one are subject to X inactivation;
however, it is well established that a number of genes escape
the silencing process. Therefore, we compared expression of
X chromosome genes in females and males, reasoning that
escape from XCI should produce a substantially higher level
of expression in females.
First we compared expression of the 11,952 expressed
autosome genes and 371 expressed X genes in 30 males and
30 females from the YRI population. Figure 2A shows median
male expression plotted against female expression for each
gene. The autosome genes lie on a diagonal with the vast
majority showing very similar expression in males and
females. Most X genes lie on the same diagonal, indicating
that X chromosome gene expression too is similar in males
and females and is not proportional to the number of X
chromosomes. These data suggest that for most X chromo-
some genes, dosage compensation is achieved between males
and females.
We then normalised expression of the 371 X chromosome
genes to the median of the 11,952 autosome genes for each
individual, and calculated the mean of the normalised X
chromosome genes for 105 males and 105 females. In each
population mean expression of X chromosome genes was
higher in females than males (Figure 2B). However, these
differences are small, representing increased expression in
females of just 2.6%, 3.4%, 1.5%, and 2.2% for CEU, CHB,
JPT and YRI, respectively. Genes escaping X inactivation do
not, therefore, have a great effect on the overall level of X-
linked gene expression in the female cell lines. This indicates
that dosage compensation is occurring effectively.
Identification and Analysis of Genes with Significantly
Higher Female Expression
Although the difference is small, there is a measurable and
consistent increase in X chromosome gene expression in
females compared to males. In order to identify the genes
that contribute to this difference, we looked for X chromo-
some genes with signiﬁcantly higher expression in females.
We used a Student’s t-test to assess differences in expression
levels between females and males within each population
separately for the 371 X chromosome genes and 11,952
autosome genes (Table S1).
Figure 3 compares the proportion of X chromosome and
autosome genes expressed more highly in females or males at
three different levels of signiﬁcance: p , 0.05, p , 0.01 and p
, 0.001. The proportion of X chromosome genes expressed
more highly in females is greater than that from autosomes in
each population. The difference between X and autosomes is
consistent across the three levels of signiﬁcance and at p ,
0.001 ranges from 3.5% to 4.9% of genes in different
populations. In contrast, the proportion of X chromosome
Figure 2. Limited Contribution of the Xi to Female Gene Expression
(A) Median expression of 11,952 autosome genes (blue) and 371 X genes
(red) for 30 YRI males plotted against median expression for 30 females.
The red diagonal indicates the expected position of X-linked genes if
expression were proportional to copy number.
(B) Expression data from 371 X chromosome genes in 105 males and 105
females were normalised to the median of 11,952 autosomal sequences.
The mean expression value for males and females in each population is
illustrated. Error bars represent þ/  1 standard deviation.
doi:10.1371/journal.pgen.0040009.g002
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Efficacy of Human Dosage Compensationgenes with higher expression in males remains similar to that
of autosome genes at all levels of signiﬁcance (Figure 3).
The most likely explanation for the observations above is
that a proportion of X chromosome genes escape from X
inactivation to a measurable level in these female cell lines.
We supposed that X-linked genes able to escape the silencing
process would be expressed more highly in females in all
populations. We also reasoned that other X-linked or
autosomal genes reaching a signiﬁcance threshold may not
do so in all populations. We therefore assessed the population
commonality of autosomal and X chromosome genes with
higher female expression at different levels of signiﬁcance
(Table 1). At p , 0.05 and p , 0.01, the proportion of genes
with signiﬁcantly higher female expression is almost identical
for autosomes and the X chromosome. However, the
distribution of genes among populations is strikingly differ-
ent, with a far greater percentage of X chromosome genes
achieving signiﬁcance in all four populations. When the
signiﬁcance threshold is raised to p , 0.001, the proportion
of genes retained is now lower for autosomes than for the X
chromosome, and no autosome gene is common to three or
four populations (Table 1). By contrast, approximately 3% of
X chromosome genes are signiﬁcantly elevated in the females
of all populations at p , 0.001 (Table 1). A single gene (CD99)
is expressed more highly in the males of all four populations
(p , 0.001). This is the only notable difference between X and
autosomes in respect of higher male expression (Table 1).
Using the combination of signiﬁcance values and popula-
tion commonality as a ﬁlter (Table 1), we identiﬁed a group of
20 X chromosome genes that are remarkable in the
consistency of their elevation across females (Table 2):
ALG13, CA5B, DDX3X, EIFIAX, EIF2S3, FUNDC1, HDHD1A,
JARID1C, MSL3L1, PCTK1, PNPLA4, PRKX, RPS4X, SMC1L1,
STS, UBE1, USP9X, UTX, ZFX and ZRSR2. Eleven of these
were expressed more highly in females at p , 0.001 in all four
populations (Table 2). This situation was not observed for any
of 11,952 autosomal genes tested.
Figure 4A illustrates the female to male ratio of expression
Figure 3. The Proportion of Genes with Higher Female Expression Is Greater from X Than Autosomes
Percentage of X chromosome and autosome genes showing higher expression in females (A–C) or males (D–F) at three levels of significance: p , 0.05, p
, 0.01, and p , 0.001. Note that the y-axis scale changes for different levels of significance.
doi:10.1371/journal.pgen.0040009.g003
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mean of the four populations, there is a subset of six genes
(JARID1C, UTX, HDHD1A, PNPLA4, DDX3X and EIF1AX) for
which expression in females is around 1.5-fold greater than in
males. Most genes have a much smaller difference: EIF2S3,
USP9X, CA5B and PCTK1, ZFX and SMC1L1 all have less than
1.2-fold higher expression in females compared to males. We
interpret these ratios as expression from the active X that is
equivalent to expression from the single X in males,
combined with a lower level of expression from the inactive
X that is more variable between genes. Some genes (e.g.,
DDX3X, STS) have a much higher ratio in some populations
than others, which may represent a biological difference in
the extent of escape from X inactivation in different human
populations.
We observe higher female expression for 5.4% of the X
chromosome genes expressed in the cell lines (20/371). The
possibility remains that other X-linked genes may escape
from XCI in lymphoblastoid cells. However, we have
determined that these 20 genes account for almost all of
the difference in gene expression between males and females
seen in Figure 2B (data not shown). Therefore, any expression
of additional genes from the inactive X chromosome must be
very low and/or must occur in only a small fraction of female
cell lines. In either case, the impact on dosage compensation
at the population level would be minimal. Therefore, we
conclude that 94.6% of X-linked genes are effectively dosage
compensated in human lymphoblastoid cell lines.
Genes with Higher Female Expression Do Not Show
Greater Variation in Expression among Females
We hypothesized that escape from XCI may be partly
stochastic, and that this might lead to greater variation in
expression levels among females than males for some genes.
Figure 4B shows box and whisker plots for four of the genes
that can be considered to escape from XCI on the basis of
their higher female expression. The other 16 genes follow a
similar pattern (data not shown). The size of the box
(interquartile range) is a good indicator of the similarity of
distribution between females and males. In the majority of
cases there is little difference in the distribution or range of
values between the sexes, although the female values have a
higher median and therefore the entire plot is shifted
upwards. There is no correlation between the size of the
interquartile range and median expression level. We also
calculated the variance for each gene and found no
signiﬁcant difference between males and females within each
Table 1. Observing a Clear Difference between X Chromosome and Autosome Genes in Respect of Higher Female Expression
Category Number of Populations Higher Expression in Females Higher Expression in Males
p , 0.05 p , 0.01 p , 0.001 p , 0.05 p , 0.01 p , 0.001
Autosomes 1 Population 30.25% 17.21% 4.70% 26.63% 12.42% 3.26%
2 Populations 6.02% 0.96% 0.03% 4.11% 0.74% 0.03%
3 Populations 0.56% 0.04% 0 0.41% 0.03% 0
4 Populations 0.03% 0.01% 0 0.03% 0 0
X Chromosome 1 Population 24.53% 11.86% 4.31% 19.41% 9.70% 2.70%
2 Populations 6.47% 2.43% 1.62%
a 2.96% 0.54% 0
3 Populations 1.35% 0.54%
a 0.81%
a 1.35% 0 0
4 Populations 4.04%
a 3.77%
a 2.96%
a 0.27%
a 0.27%
a 0.27%
a
False discovery rate 1 Population 17.1475% 3.8812% 0.3988%
2 Populations 1.3538% 0.0588% 0.0006%
3 Populations 0.0475% 0.0004% ,0.0001%
4 Populations 0.0006% ,0.0001% ,0.0001%
Percentages of autosome and X chromosome genes with higher expression in females or males are shown at three levels of significance (values are given to two decimal places). The
percentage of genes with significantly different expression between males and females in one, two, three, or four study populations is shown. Note that these figures have not been
corrected for multiple testing, since we use the table as a filter rather than to predict absolute percentages. However, we have included false discovery rates to show the percentage of
genes in each category that would be expected by chance to reject a true null hypothesis that female and male expression are equivalent.
aValues show where there is an obvious difference between the X chromosome and autosomes.
doi:10.1371/journal.pgen.0040009.t001
Table 2. Genes Expressed More Highly in Females That Fit the
Criteria for Escaping X Inactivation
Gene Number of Populations with
Significantly Higher Expression in Females
p , 0.05 p , 0.01 p , 0.001
DDX3X 444
EIF1AX 444
EIF2S3 444
FUNDC1 444
HDHD1A 444
JARID1C 444
PNPLA4 444
RPS4X 444
USP9X 444
UTX 444
ZRSR2 444
PRKX 443
UBE1 443
ZFX 442
ALG13 332
SMC1L1 322
CA5B 222
MSL3L1 222
STS 222
PCTK1 421
The number of populations in which significance is achieved is shown for three p-values.
doi:10.1371/journal.pgen.0040009.t002
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Efficacy of Human Dosage CompensationFigure 4. Comparison of Female and Male Expression of Genes with Higher Female Expression
(A) Female to male expression ratio for 20 genes expressed more highly in females in four human populations. Expression in females is typically 10%–
50% higher than in males.
(B) Box and whisker plots showing the median, distribution, and range of expression for females and males for four X chromosome genes with higher
female expression. The median is indicated by the red line, the box shows the interquartile range, and the ends of the whiskers the maxima and minima.
The y-axis spans a 4-fold range for each graph to enable direct comparison of different genes.
(C) Scatter plot of expression values of four non-dosage compensated genes in 30 males and 30 females from the YRI population. JARID1C is unique as
none of the males has higher expression than any of the females. For EIF2S3 the overlap is considerable, as only half the females have higher expression
than the highest male and only five males express at a level below the lowest female.
doi:10.1371/journal.pgen.0040009.g004
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Efficacy of Human Dosage Compensationpopulation (unpublished data). We conclude that genes
escaping XCI in these cell lines are not expressed more
variably in females than males, which suggests that escape
may be a tightly regulated rather than a stochastic event.
While the medians and interquartile ranges are clearly
different between males and females, there is considerable
overlap between the distributions of the expression levels of
the two datasets. Individual data points from males and
females of the YRI population are shown for four genes
escaping XCI as a scatter graph (Figure 4C). JARID1C is
unique in that all data points for females are higher than all
data points for males. For the other 19 genes, the female and
male datasets overlap to varying extents (contrast EIF2S3 with
RPS4X in Figure 4C). This can also be seen as overlap of
whiskers in Figure 4B. This observation illustrates the extent
of inter-individual variability of gene expression and high-
lights the importance of comparing large samples of males
and females to identify differences in gene expression that
are a consequence of escape from XCI.
PAR1 Genes Have Equal Expression from X and Y
Chromosomes
The genes from the pseudoautosomal regions (PARs) are a
special case as they lie within regions of XY recombination
and are essentially equivalent on the X and Y chromosomes.
For genes in PAR1, escape from XCI is generally believed to
be a prerequisite for dosage compensation between the two
female X chromosomes and the male X and Y. We found that
twelve PAR1 genes show no signiﬁcant difference between
females and males across populations and are therefore
dosage compensated (Table S1). The only exception is CD99,
which is expressed signiﬁcantly more highly in males in all
four populations (p , 0.001).
We identiﬁed single nucleotide polymorphisms (SNPs) in
PAR1 genes SLC25A6, CXYorf3, ZBED1 and CD99 and used a
quantitative assay to measure relative expression from the X
and Y alleles in heterozygous males. As shown in Table 3, the
relative contribution from the X and Y chromosomes is very
similar for each of the four genes. We conclude that the
majority of PAR1 genes escape from XCI and are dosage
compensated, consistent with the expectation above.
Evidence That Dosage Compensation of Some X-Linked
Genes Is Maintained through Expression of a Y-Linked
Copy
The majority of genes that have a functional Y chromo-
some homologue were found to be expressed in hybrid cells
containing the Xi [16]. Therefore, we decided to test the
possibility that genes with higher female expression might,
like the genes in PAR1, be compensated by functionally
equivalent Y-linked copies. Eight of the 20 genes with higher
female expression have functional Y-linked gametologues. We
excluded PRKY and EIF1AY from the analysis. The PRKY
probe has 94% sequence identity to PRKX and gives a strong
signal in females. Expression of EIF1AY is approximately 13-
fold greater than EIF1AX in males, suggesting that EIF1AY is
not involved in a compensation mechanism. Gene expression
for the remaining six X-Y gene pairs is shown in Figure 5.
USP9X expression is signiﬁcantly higher in females at p ,
0.001 in all populations. Interestingly, the sum of USP9X and
USP9Y expression in males is not signiﬁcantly different from
the level of USP9X in females (p ¼ 0.822 [CEU], p ¼ 0.024
[CHB], p¼0.245 [JPT] and p¼0.610 [YRI]). USP9Y expression
therefore completely restores the USP9X dosage imbalance
between males and females. Figure 5B–5D shows similar
results for gene pairs RPS4X/RPS4Y1, UTX/UTY and DDX3X/
DDX3Y. In each case dosage from the X and Y copies in males
is similar to that of the X copies in females. Expression of the
Y copy is always much lower than expression of the X copy
and appears to reﬂect the expression from the Xi. For these
four genes, dosage compensation appears to be achieved by
expression of the Y copy. In contrast, expression levels of
JARID1C (X) and JARID1D (Y) (Figure 5E) are approximately
equal and their combined expression in males is signiﬁcantly
greater than JARID1C expression in females. A similar picture
is obtained with ZFX and ZFY in males (Figure 5F). We have
identiﬁed an X-Y gene pair (TMSB4X/TMSB4Y) whose X copy
is dosage compensated according to our data. TMSB4Y is
expressed at less than 1% of the level of TMSB4X and
Table 3. Genes in the Pseudoautosomal Region (PAR1) Are Expressed Equally from the X and Y Chromosomes in Male Cell Lines
Gene Ref SNP ID Ref SNP
Alleles
Number of Cell Lines Expression (Percent) Range of Expression (Percent)
Allele 1 Allele 2 Allele 1 Allele 2
SLC25A6 rs7205 C/T 5 50.4 49.6 46.1–58.5 41.5–53.9
CXYorf3 rs1128551 G/A 5 49.2 50.8 45.8–52.5 47.5–54.2
CXYorf3 rs6644621 C/T 4 51.4 48.6 48.8–52.6 47.4–51.2
ZBED1 rs567595 G/A 2 55.2 44.8 50.7–59.8 40.2–49.3
ZBED1 rs1044307 C/T 5 48.8 51.2 44.4–53.5 46.5–55.6
ZBED1 rs17842876 C/T 6 48.6 51.4 44.5–50.2 49.8–55.5
ZBED1 rs7057630 C/T 3 47.6 52.4 43.9–51.9 48.1–56.1
ZBED1 rs3203783 G/T 4 46.5 53.5 44.0–51.8 48.2–56.0
CD99 rs17849631 C/T 3 52.1 47.9 45.1–58.5 41.5–54.9
CD99 rs11556080 G/A 2 49.3 50.7 48.0–50.6 49.4–52.0
CD99 rs4575010 C/T 2 52.8 47.2 52.7–53.0 47.0–47.3
CD99 rs6661 C/T 1 50.6 49.4 Not available Not available
SNPs were identified in expressed genes and assayed in cDNA by SNaPSHOT. Peak heights for each allele were normalised to genomic DNA and expressed as a percentage of the total. The
range of values for each SNP is also shown.
doi:10.1371/journal.pgen.0040009.t003
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males and females.
Genes with Higher Female Expression Are Not Distributed
Evenly on the X Chromosome
Genes that escape from XCI in hybrid cell lines are non-
randomly distributed on the X chromosome [16,17]. In light
of identifying a smaller proportion of genes with higher
female expression, we assessed the relationship between gene
expression and chromosomal location. We observed that the
distribution of genes with elevated female expression is also
non-random, with most lying on the short arm (Figure 6). The
chromosome can be divided into strata that ceased to
recombine with the Y chromosome at different times in
evolutionary history [17,26]. The most ancient parts of the
chromosome (strata S1 and S2), covering the long arm and
proximal short arm, contain 287 of the 371 expressed genes,
but only six that have higher female expression. By contrast, a
larger fraction of genes have elevated female expression levels
in regions that stopped recombining with the Y chromosome
Figure 5. Evidence That Expression of the Y-linked Copy of XY Gene Pairs Can Maintain Dosage Compensation
(A–F) Stacked bars show the cumulative expression of X and Y gametologues in males alongside expression from the X chromosomes in females. Note
that the y-axis is a linear scale.
doi:10.1371/journal.pgen.0040009.g005
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Efficacy of Human Dosage Compensationmore recently, either in early eutherian mammals (S3) or in
primates (S4, S5). Ten out of 66 S3 genes ﬁt this picture, while
all three expressed genes in S4, together with the single
example in S5, are more highly expressed in females. These
ﬁndings support the model that X-linked genes are recruited
into the XCI system following the Y chromosome degener-
ation that occurs when regions cease to recombine [27].
Discussion
On the basis of these data, we suggest that dosage
compensation in human lymphoblastoid cells is virtually
complete. Gene expression from the single X chromosome in
males is upregulated 2-fold compared to the autosomes.
Expression from the female X chromosome pair is almost the
same as from the male X, suggesting that few genes escape the
silencing process to any great extent. Twenty genes in this
study (5.4%) have signiﬁcantly higher female expression, and
four of these could have dosage balance maintained through
expression of a Y-linked homologue.
Ohno predicted 40 years ago that the evolution of a dosage
compensation mechanism in mammals must have involved a
doubling of expression of each X-linked gene as the Y
chromosome degenerated [4]. Two-fold upregulation of the X
chromosome has now been demonstrated for both humans
and mice [5,6] and in a range of tissues [5]. In D. melanogaster,a
slight but signiﬁcant overexpression of the X chromosome
compared to the autosomes in all XX;AA samples has been
reported [6] which may be due to inherent hypertranscrip-
tion of the X chromosome. We have determined that human
X chromosome expression is not signiﬁcantly elevated above
the autosome average, suggesting that the X chromosome is
not hypertranscribed in the cell lines over and above the 2-
fold upregulation. Our data show that upregulation occurs
precisely and consistently in 105 individual male samples, also
leading us to conclude that in lymphoblastoid cell lines gene
expression is appropriately regulated.
Upregulation of the X is not seen in mouse germ cells
suggesting that it takes place in the developing embryo [5].
Two-fold upregulation may be a general feature of X
chromosomes, affecting genes on Xa and those on Xi that
escape inactivation. Alternatively, upregulation and silencing
could be mutually exclusive choices for X chromosomes in
embryogenesis, simultaneously achieving correct X gene
expression and dosage compensation. Previously, genes have
been classiﬁed as partially escaping XCI if their female to
male expression ratio is below two. However, under the
second model described, genes fully expressed from both Xi
and an upregulated Xa in females would have a theoretical
maximum expression that is 1.5-fold greater in females than
males. We favour this model as we have identiﬁed six genes
expressed approximately 1.5-fold more highly in females and
the greatest ratio we observe for any gene is 1.56, averaged
across four populations.
Is 2-fold upregulation a chromosome-wide phenomenon?
The PAR1 region is the only surviving remnant of a large
autosomal addition to both sex chromosomes that still
undergoes recombination in male meiosis. The X and Y
chromosomes are equivalent in PAR1 and genes here are
predicted to escape XCI. Accordingly, all PAR1 genes tested
were expressed from Xi in hybrid cell lines [16]. The majority
of PAR1 genes included in our study showed no signiﬁcant
difference in expression between females and males. This
gives rise to two models for PAR1 gene expression. In the
ﬁrst, PAR1 genes have equal expression from Xa,X i and Y
copies and so no dosage compensation is necessary. Under
this model, PAR1 is excluded from both the upregulation and
the silencing components of dosage compensation. In the
second model, the PAR1 is 2-fold upregulated on the Xa only
and dosage compensation is achieved through equal expres-
sion from the Xi and Y copies. A corollary of this model is
unequal expression of PAR1 alleles within a cell, but equal
expression between males and females. We have tested three
dosage compensated PAR1 genes in males and ﬁnd that
expression levels are similar from the X and Y alleles.
Therefore, we favour the ﬁrst model and propose that
PAR1 is protected from both upregulation and silencing.
CD99 is the only PAR1 gene found to be more highly
expressed in males, yet has equivalent expression from the X
and Y copies. CD99 is the gene that lies closest to the
boundary between the PAR1 and X-linked material, and we
suggest that spreading of the XCI signal across the pseu-
doautosomal boundary results in partial silencing of CD99.
Consistent with this hypothesis, the protein product of the
CD99 gene was found to be present at lower levels in hybrids
containing Xi than those containing Xa [28].
Outside the pseudoautosomal regions, twenty genes are
expressed at signiﬁcantly higher levels in female cell lines. We
hypothesized that these genes would escape from XCI.
Formally, the alternative explanation for the elevated female
expression could be that these genes are hypertranscribed
from the female active X chromosome. However, since all of
these genes are included in previous reports of escape from
XCI [12,15,16,29–33], we prefer the former explanation for
higher female expression. An intriguing observation is that
the dosage of some of these genes could be effectively
compensated by expression of a Y copy. An underlying
assumption of this analysis is that the X and Y gametologues
are functionally equivalent, despite their evolutionary diver-
gence. The DEAD box RNA helicase proteins DDX3X and
Figure 6. Genes Expressed More Highly in Females Are Distributed Non-
Randomly on the X Chromosome
For each gene, the median expression value for males was subtracted
from the median expression value for females to give a median
difference. Illustrated is the median difference for each gene based on
averaging the values for the four populations, plotted according to
location on the X chromosome. A median difference of 1 represents a 2-
fold difference in expression. Different symbols represent different
evolutionary strata. Genes expressed significantly more highly in females
are coloured red, and the single gene expressed significantly more highly
in males (CD99) is coloured blue.
doi:10.1371/journal.pgen.0040009.g006
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temperature-sensitive mutant hamster cell line incapable of
growth at a non-permissive temperature [34]. The ribosomal
proteins RPS4Y1 and RPS4X show functional equivalence in a
similar rescue assay and can function interchangeably in
ribosomes [35]. RPS4Y1 and RPS4X are among a very small
number of genes from the ancient sex chromosomes that
have functional Y copies [17]. Despite their considerable
divergence time and very high synonymous substitution rate,
their protein products share 93% identity and are the same
length, consistent with their being functionally equivalent.
Previous microarray studies have assessed escape from XCI
by looking for increased expression in cell lines with
supernumerary X chromosomes [18] or by comparing female
and male expression [19,20]. More recently, a larger study
assessed genome-wide sex differences in gene expression
using lymphoblastoid cell lines from monozygotic twin pairs
[21]. Each study reports some genes that are considered to be
well established as escaping from XCI, but the four vary
considerably in the number and identity of genes docu-
mented. These differences might be explained in part by
variation in escape from X inactivation in different tissues,
for which there is evidence [20]. However, a further
possibility is that inter-individual variability in expression
that is unrelated to XCI could increase the risk of false
positives or negatives where the sample size is small. The scale
of our study, which measured gene expression in 210
individuals for 81% of protein coding genes on the X
chromosome, means that we can conﬁdently detect signiﬁ-
cantly higher expression in females at the population level in
spite of this factor. Notably the study by McRae et al. [21],
which assayed 38 lymphoblastoid cell lines, agrees most
closely with our study in the identity and proportion of genes
with higher female expression.
We ﬁnd that 5.4% of X-linked genes have increased female
expression in the cell lines. Analysis of somatic-cell hybrids
that retain Xi and of ﬁbroblast cells with non-random XCI has
put the proportion of genes escaping XCI at 15%–25% [16].
This difference could be explained by a lower proportion of
genes escaping XCI in lymphoblastoid compared with
ﬁbroblast (or hybrid) cells. However, perhaps more important
are the differences of approach between the two studies. Our
study used a population based analysis of dosage compensa-
tion, whereas Carrel and Willard [16] detected expression in
hybrid cell lines, or compared expression levels from Xa and
Xi alleles in female cell lines, using methods capable of
detecting very low levels of expression from Xi. Some genes,
therefore, could be expressed from Xi but at a level that is
insufﬁcient to cause a dosage imbalance. Other genes could
escape to a larger extent in a small number of females, as
suggested by Carrel and Willard [16]. Neither of these,
though, is substantial enough to generate a signiﬁcant sex-
difference at the population level.
We conclude that dosage compensation in human lympho-
blastoid cell lines is highly effective and tightly controlled. It
will be interesting to extend these studies to other tissues, but
it seems unlikely that this level of regulation would be
restricted to this single cell type. Therefore, we propose that
the contribution of escape from XCI to male-female pheno-
typic differences may be small and furthermore, we suggest
that the number of genes contributing to phenotype in X
chromosome aneuploidies is lower than previously thought.
Materials and Methods
Generation of dataset. Gene expression was assayed in lympho-
blastoid cell lines of all 210 unrelated HapMap individuals [25] from
four populations (CEU: 60 (30 Male/30 Female) Utah residents with
ancestry from northern and western Europe; CHB: 45 (22M/23F) Han
Chinese in Beijing; JPT: 45 (23M/22F) Japanese in Tokyo and YRI: 60
(30M/30F) Yoruba in Ibadan, Nigeria). RNA preparation, labeling,
hybridization to Sentrix Human-6 BeadChip (Illumina), gene
expression quantiﬁcation and normalization of raw data were
described previously [23]. Brieﬂy, each RNA sample was labelled in
duplicate and each labelled sample was hybridised to two separate
arrays. Data were subjected to quantile normalization then were
median normalized across all individuals. Final data points for each
gene are the mean of the four normalized hybridisation values. Log2
transformed mRNA expression values were used throughout except
where otherwise stated. Data can be downloaded from http://www.
sanger.ac.uk/humgen/genevar/ and the Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) entry GSE6536.
Selection of expression data for analysis. We established an
appropriate cut-off point for evaluating gene expression by
examination of four non-human probes (lysA, pheA, thrB and trpF)
in 210 individuals: 836/840 data points had log2 expression values
,6.4. We also evaluated signals from Y-linked genes in female
samples: 593/620 data points were found to have values ,6.4,
excluding two probes that apparently cross-hybridised with X-linked
genes. We conservatively chose to analyse genes with log2 median
expression .6.4 in all four populations. We excluded redundant
probes (n ¼ 21) for X chromosome genes and any X probes that
matched autosomal exons. Data for 11,952 expressed autosome
sequences and 371 expressed X chromosome genes were used in all
downstream analyses. The complete set of X chromosome and
autosomal genes represented in this study and median expression
values are shown in Table S2.
Statistical analysis. Data from the four populations were consid-
ered separately throughout. We tested male and female datasets
separately for skewness and kurtosis for 371 X chromosome probes
and found no evidence for them, except for a very small number of
genes in some populations where log2 expression was close to the
expression cutoff of 6.4. We therefore concluded that the gene
expression data generally follow a normal distribution. We used
median values to illustrate chromosome or population averages
except where we have shown the standard deviation (Figure 2B). To
make comparisons between autosome genes and X genes, or between
groups of individuals, we normalized all gene expression values to the
median value of 11,952 autosomal probes for each individual. We
compared the variances of male and female samples for X
chromosome genes by placing the larger variance over the smaller
to form an F statistic. We found that variances for females and males
are not signiﬁcantly different. We tested signiﬁcance by calculating p-
values associated with a Student’s two sample homoscedastic t-test
with a two-tailed distribution. The complete list of p-values is shown
in Table S1.
Allele-speciﬁc gene expression analysis. SNaPshot was carried out
on cDNA and genomic DNA from heterozygous males using the
SNaPshot Multiplex Kit (Applied Biosystems) according to the
manufacturer’s instructions with the following modiﬁcations. Initial
template generation was carried out using Platinum Taq polymerase
(Invitrogen) in a standard reaction using touchdown polymerase
chain reaction (PCR): denaturation: 948C 15 min; 20 cycles: 948C3 0
sec, 708C, 30 sec reducing by 18C per cycle, 728C 45 sec; then 15 cycles:
948C 30 sec, 508C 30 sec, 728C 45 sec; ﬁnal extension 728C for 7 min.
PCR products were treated with 2 units of shrimp alkaline
phosphatase (USB) and 1.5 units of Exonuclease I (USB) for 1 hour
at 378C to remove primers and nucleotides, then at 808C for 15 mins.
Primer extension products were analysed on an ABI 3730 DNA
Analyzer with a POP-7 Polymer and a 36cm capillary array with the
ABI standard run module. SNP data were analysed using ABI PRISM
GeneMapper Software Version 3.0. Primers used to generate
template DNA for analysis and SNaPshot extension primers are
shown in Table S3. Peak heights from cDNA were normalized to
genomic DNA values and expressed as an allelic ratio.
Supporting Information
Table S1. XX and XY Normalised Medians and Means and p-Value
Associated with Student’s t-test
Found at doi:10.1371/journal.pgen.0040009.st001 (5.5 MB XLS).
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Found at doi:10.1371/journal.pgen.0040009.st002 (2.0 MB XLS).
Table S3. SNaPshot Primers (59–39)
Found at doi:10.1371/journal.pgen.0040009.st003 (21 KB XLS).
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